{"id":723,"date":"2026-07-31T22:46:30","date_gmt":"2026-07-31T22:46:30","guid":{"rendered":"https:\/\/neolyspharma.ca\/?post_type=member&#038;p=723"},"modified":"2026-07-31T22:46:30","modified_gmt":"2026-07-31T22:46:30","slug":"hugo-gagnon","status":"publish","type":"member","link":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/","title":{"rendered":"Hugo Gagnon"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Hugo Gagnon is a biotechnology entrepreneur and executive with more than 15 years of experience at the intersection of multi-omics, drug development, and company building. Trained in biochemistry, pharmacology, and proteomics, he brings deep expertise in mass spectrometry, LC-MS\/MS, and multi-omics data integration. His career quickly moved beyond the laboratory: he founded and scaled an academic spinout into a successful multi-omics contract research organization, leading strategy, operations, business development, and financing.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As Chief Executive Officer of Neolys Pharma, he combines scientific depth with entrepreneurial leadership to advance the development of novel oncology therapies. His strength is translating scientific complexity, whether data quality, mechanistic relevance, or development risk, into clear strategies for teams, partners, investors, and the board.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[17],"class_list":["post-723","member","type-member","status-publish","hentry","category-co-founder"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Hugo Gagnon | Chief Executive Officer, Neolys Pharma<\/title>\n<meta name=\"description\" content=\"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hugo Gagnon | Chief Executive Officer, Neolys Pharma\" \/>\n<meta property=\"og:description\" content=\"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/\" \/>\n<meta property=\"og:site_name\" content=\"Neolyspharma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/hugo-gagnon\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/hugo-gagnon\\\/\",\"name\":\"Hugo Gagnon | Chief Executive Officer, Neolys Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\"},\"datePublished\":\"2026-07-31T22:46:30+00:00\",\"description\":\"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/hugo-gagnon\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/hugo-gagnon\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/member\\\/hugo-gagnon\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hugo Gagnon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"name\":\"Neolys Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\"},\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\",\"name\":\"Neolys Pharma inc.\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"contentUrl\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"width\":512,\"height\":242,\"caption\":\"Neolys Pharma inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neolys-pharma\"],\"legalName\":\"Neolys Pharma inc.\",\"telephone\":\"+1-418-931-2195\",\"email\":\"info@neolyspharma.ca\",\"description\":\"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Hugo Gagnon | Chief Executive Officer, Neolys Pharma","description":"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/","og_locale":"en_US","og_type":"article","og_title":"Hugo Gagnon | Chief Executive Officer, Neolys Pharma","og_description":"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.","og_url":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/","og_site_name":"Neolyspharma","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/","url":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/","name":"Hugo Gagnon | Chief Executive Officer, Neolys Pharma","isPartOf":{"@id":"https:\/\/neolyspharma.ca\/en\/#website"},"datePublished":"2026-07-31T22:46:30+00:00","description":"Hugo Gagnon, Ph. D., Chief Executive Officer of Neolys Pharma, biotechnology entrepreneur and executive.","breadcrumb":{"@id":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neolyspharma.ca\/en\/member\/hugo-gagnon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neolyspharma.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Hugo Gagnon"}]},{"@type":"WebSite","@id":"https:\/\/neolyspharma.ca\/en\/#website","url":"https:\/\/neolyspharma.ca\/en\/","name":"Neolys Pharma","description":"","publisher":{"@id":"https:\/\/neolyspharma.ca\/en\/#organization"},"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/neolyspharma.ca\/en\/#organization","name":"Neolys Pharma inc.","url":"https:\/\/neolyspharma.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","contentUrl":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","width":512,"height":242,"caption":"Neolys Pharma inc."},"image":{"@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neolys-pharma"],"legalName":"Neolys Pharma inc.","telephone":"+1-418-931-2195","email":"info@neolyspharma.ca","description":"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers."}]}},"_links":{"self":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/member\/723","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/member"}],"about":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/types\/member"}],"wp:attachment":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/media?parent=723"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/categories?post=723"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}